{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04064827",
            "orgStudyIdInfo": {
                "id": "M11-617"
            },
            "organization": {
                "fullName": "AbbVie",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)",
            "officialTitle": "A Phase 3, Prospective, Open-Label, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Paricalcitol Oral Solution for the Treatment of Secondary Hyperparathyroidism in Pediatric Subjects Ages 0 to 9 Years With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis",
            "therapeuticArea": [
                "Nephrology and Renal Diseases",
                "Other"
            ],
            "study": "a-study-to-evaluate-safety-efficacy-and-pharmacokinetics-of-paricalcitol-for-treatment-of-secondary-hyperparathyroidism-shpt-in-pediatric-participants-with-stage-chronic-kidney-disease-ckd"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2020-09-16",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-06-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-10-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2019-08-20",
            "studyFirstSubmitQcDate": "2019-08-20",
            "studyFirstPostDateStruct": {
                "date": "2019-08-22",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-24",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-25",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "AbbVie",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": true
        },
        "descriptionModule": {
            "briefSummary": "The main objective of this study is to evaluate the safety, efficacy and pharmacokinetics of paricalcitol oral solution in pediatric participants of ages 0 to 9 years with SHPT associated with stage 5 CKD receiving Peritoneal Dialysis (PD) or Hemodialysis (HD). The 24-week study is divided into two 12-week dosing periods (Dosing Period 1 followed by Dosing Period 2)."
        },
        "conditionsModule": {
            "conditions": [
                "Chronic Kidney Disease (CKD)",
                "Secondary Hyperparathyroidism (SHPT)"
            ],
            "keywords": [
                "Chronic Kidney Disease",
                "Paricalcitol",
                "Hyperparathyroidism",
                "Pediatric Subjects",
                "Peritoneal Dialysis (PD)",
                "Hemodialysis (HD)",
                "Intact parathyroid hormone (iPTH)"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 16,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Participants Receiving Paricalcitol",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will be administered paricalcitol three times a week (TIW) but no more frequently than every other day for 24 weeks",
                    "interventionNames": [
                        "Drug: Paricalcitol"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Paricalcitol",
                    "description": "Paricalcitol oral solution (2.5 mcg/mL) will be administered with an oral dispenser",
                    "armGroupLabels": [
                        "Participants Receiving Paricalcitol"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Percentage of Participants Who Achieve Positive Response During Dosing Period 1",
                    "description": "Positive response is defined as having two consecutive \\>= 30% reductions from baseline in intact parathyroid hormone (iPTH) or two consecutive iPTH values in the target range between 150 picograms (pg)/milliliters (mL) to 300 pg/mL (16.5-33.0 picomole\\[pmol\\]/L).",
                    "timeFrame": "Up to Week 12"
                },
                {
                    "measure": "Incidence of Hypercalcemia During Dosing Period 1",
                    "description": "Incidence of hypercalcemia is defined as two consecutive, post-baseline, corrected calcium measurements above the normal participants's age-specific upper limit.",
                    "timeFrame": "Up to Week 12"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Percentage of Participants Who Achieve a Positive Response During Dosing Period 2",
                    "description": "Positive response is defined as having two consecutive \\>= 30% reductions from baseline in iPTH or two consecutive iPTH values in the target range between 150 pg/mL to 300 pg/mL (16.5-33.0 picomole\\[pmol\\]/L).",
                    "timeFrame": "Week 12 through Week 24"
                },
                {
                    "measure": "Percentage of Participants Who Achieve a Positive Response During Dosing Periods 1 and 2 Combined",
                    "description": "Positive response is defined as having two consecutive \\>= 30% reductions from baseline in iPTH or two consecutive iPTH values in the target range between 150 pg/mL to 300 pg/mL (16.5-33.0 picomole\\[pmol\\]/L).",
                    "timeFrame": "Up to Week 24"
                },
                {
                    "measure": "Percentage of Participants Who Achieve Two Consecutive >= 30% Reductions in iPTH From Baseline During Dosing Period 1",
                    "description": "Participants who achieve two consecutive \\>= 30% reductions in iPTH will be evaluated.",
                    "timeFrame": "Up to Week 12"
                },
                {
                    "measure": "Percentage of Participants Who Achieve Two Consecutive >= 30% Reductions in iPTH From Baseline During Dosing Period 2",
                    "description": "Participants who achieve two consecutive \\>= 30% reductions in iPTH will be evaluated.",
                    "timeFrame": "Week 12 through Week 24"
                },
                {
                    "measure": "Percentage of Participants Who Achieve Two Consecutive >= 30% Reductions in iPTH From Baseline During Dosing Periods 1 and 2 Combined",
                    "description": "Participants who achieve two consecutive \\>= 30% reductions in iPTH will be evaluated.",
                    "timeFrame": "Up to Week 24"
                },
                {
                    "measure": "Percentage of Participants Who Achieve Two Consecutive iPTH Values Between 150 pg/mL to 300 pg/mL (16.5 - 33.0 pmol/L) During Dosing Period 1",
                    "description": "Participants who achieve two consecutive iPTH values between 150 pg/mL to 300 pg/mL (16.5 - 33.0 pmol/L) will be evaluated.",
                    "timeFrame": "Up to Week 12"
                },
                {
                    "measure": "Percentage of Participants Who Achieve Two Consecutive iPTH Values Between 150 pg/mL to 300 pg/mL (16.5 - 33.0 pmol/L) During Dosing Period 2",
                    "description": "Participants who achieve two consecutive iPTH values between 150 pg/mL to 300 pg/mL (16.5 - 33.0 pmol/L) will be evaluated.",
                    "timeFrame": "Week 12 through Week 24"
                },
                {
                    "measure": "Percentage of Participants Who Achieve Two Consecutive iPTH Values Between 150 pg/mL to 300 pg/mL (16.5 - 33.0 pmol/L) During Dosing Periods 1 and 2 Combined",
                    "description": "Participants who achieve two consecutive iPTH values between 150 pg/mL to 300 pg/mL (16.5 - 33.0 pmol/L) will be evaluated.",
                    "timeFrame": "Up to Week 24"
                },
                {
                    "measure": "Incidence of Hypercalcemia During Dosing Period 2",
                    "description": "Incidence of hypercalcemia is defined as two consecutive, post-baseline, corrected calcium measurements above the normal participants's age-specific upper limit.",
                    "timeFrame": "Week 12 through Week 24"
                },
                {
                    "measure": "Incidence of Hypercalcemia During Dosing Periods 1 and 2 Combined",
                    "description": "Incidence of hypercalcemia is defined as two consecutive, post-baseline, corrected calcium measurements above the normal participants's age-specific upper limit.",
                    "timeFrame": "Up to Week 24"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Participant is currently diagnosed with and/or being treated for secondary hyperparathyroidism (SHPT).\n* Participant must be diagnosed with chronic kidney disease (CKD) stage 5 receiving peritoneal dialysis (PD) or hemodialysis (HD) for at least 30 days prior to initial Screening.\n* For entry into the Washout Period (for vitamin D receptor activator \\[VDRA\\] non-naive participants), the participant must meet the appropriate laboratory criteria based upon the participant's age as described in the protocol.\n* For entry into the Dosing Period (for VDRA-naive participants or VDRA non-naive participants who have completed the Washout Period), the participant must meet the appropriate laboratory criteria based upon the participant's age as described in the protocol.\n\nExclusion Criteria:\n\n* Participant is scheduled to receive a living donor kidney transplant within 3 months of Screening or is a kidney transplant recipient.\n* Participant is expected to discontinue peritoneal dialysis (PD) or hemodialysis (HD) within 3 months of the initial Screening visit.\n* Participant has had a parathyroidectomy within 12 weeks prior to Screening.\n* Participant is taking maintenance calcitonin, bisphosphonates, glucocorticoids (in a dose equivalent to more than \\> 0.16 mg/kg/day or 5 mg prednisone/day, whichever is lower), 4 weeks prior to Dosing.\n* Participant is receiving calcimimetics at the time of Screening or is expected to initiate calcimimetics at any time throughout the study.\n* Participant is unable to take oral medications.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "0 Years",
            "maximumAge": "9 Years",
            "stdAges": [
                "CHILD"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "ABBVIE CALL CENTER",
                    "role": "CONTACT",
                    "phone": "844-663-3742",
                    "email": "abbvieclinicaltrials@abbvie.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "ABBVIE INC.",
                    "affiliation": "AbbVie",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Arkansas Children's Hospital /ID# 225417",
                    "status": "COMPLETED",
                    "city": "Little Rock",
                    "state": "Arkansas",
                    "zip": "72202",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.74648,
                        "lon": -92.28959
                    }
                },
                {
                    "facility": "Stanford University /ID# 252150",
                    "status": "RECRUITING",
                    "city": "Redwood City",
                    "state": "California",
                    "zip": "94063",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.48522,
                        "lon": -122.23635
                    }
                },
                {
                    "facility": "Children's National Medical Center /ID# 225991",
                    "status": "RECRUITING",
                    "city": "Washington",
                    "state": "District of Columbia",
                    "zip": "20010-2916",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.89511,
                        "lon": -77.03637
                    }
                },
                {
                    "facility": "Holtz Childrens Hospital, University of Miami /ID# 225636",
                    "status": "RECRUITING",
                    "city": "Miami",
                    "state": "Florida",
                    "zip": "33136-1005",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 25.77427,
                        "lon": -80.19366
                    }
                },
                {
                    "facility": "Nicklaus Children's Hospital /ID# 210517",
                    "status": "COMPLETED",
                    "city": "Miami",
                    "state": "Florida",
                    "zip": "33155-3009",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 25.77427,
                        "lon": -80.19366
                    }
                },
                {
                    "facility": "Emory University /ID# 140665",
                    "status": "COMPLETED",
                    "city": "Atlanta",
                    "state": "Georgia",
                    "zip": "30322-1014",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.749,
                        "lon": -84.38798
                    }
                },
                {
                    "facility": "Boston Children's Hospital /ID# 162863",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02115",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Duplicate_Levine Children's Specialty Center- Charlotte /ID# 216057",
                    "status": "COMPLETED",
                    "city": "Charlotte",
                    "state": "North Carolina",
                    "zip": "28203-5866",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.22709,
                        "lon": -80.84313
                    }
                },
                {
                    "facility": "Children's Hospital of Philadelphia - Main /ID# 213802",
                    "status": "RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19104-4319",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                },
                {
                    "facility": "University of Texas Southwestern Medical Center /ID# 210495",
                    "status": "RECRUITING",
                    "city": "Dallas",
                    "state": "Texas",
                    "zip": "75390-7208",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.78306,
                        "lon": -96.80667
                    }
                },
                {
                    "facility": "University of Utah /ID# 140669",
                    "status": "RECRUITING",
                    "city": "Salt Lake City",
                    "state": "Utah",
                    "zip": "84112-5500",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.76078,
                        "lon": -111.89105
                    }
                },
                {
                    "facility": "Seattle Children's Hospital /ID# 162861",
                    "status": "COMPLETED",
                    "city": "Seattle",
                    "state": "Washington",
                    "zip": "98105",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 47.60621,
                        "lon": -122.33207
                    }
                },
                {
                    "facility": "School of Medicine University of Puerto Rico-Medical Science Campus /ID# 140663",
                    "status": "RECRUITING",
                    "city": "San Juan",
                    "zip": "00935",
                    "country": "Puerto Rico",
                    "contacts": [
                        {
                            "name": "Site Coordinator",
                            "role": "CONTACT",
                            "phone": "844-663-3742"
                        }
                    ],
                    "geoPoint": {
                        "lat": 18.46633,
                        "lon": -66.10572
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Related Info",
                    "url": "https://www.abbvieclinicaltrials.com/study/?id=M11-617"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP",
                "CSR"
            ],
            "timeFrame": "For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/",
            "accessCriteria": "Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/",
            "url": "https://vivli.org/ourmember/abbvie/"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009362",
                    "term": "Neoplasm Metastasis"
                },
                {
                    "id": "D000007674",
                    "term": "Kidney Diseases"
                },
                {
                    "id": "D000051436",
                    "term": "Renal Insufficiency, Chronic"
                },
                {
                    "id": "D000006961",
                    "term": "Hyperparathyroidism"
                },
                {
                    "id": "D000006962",
                    "term": "Hyperparathyroidism, Secondary"
                }
            ],
            "ancestors": [
                {
                    "id": "D000014570",
                    "term": "Urologic Diseases"
                },
                {
                    "id": "D000052776",
                    "term": "Female Urogenital Diseases"
                },
                {
                    "id": "D000005261",
                    "term": "Female Urogenital Diseases and Pregnancy Complications"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                },
                {
                    "id": "D000051437",
                    "term": "Renal Insufficiency"
                },
                {
                    "id": "D000002908",
                    "term": "Chronic Disease"
                },
                {
                    "id": "D000020969",
                    "term": "Disease Attributes"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000009385",
                    "term": "Neoplastic Processes"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000010279",
                    "term": "Parathyroid Diseases"
                },
                {
                    "id": "D000004700",
                    "term": "Endocrine System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10698",
                    "name": "Kidney Diseases",
                    "asFound": "Kidney Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12307",
                    "name": "Neoplasm Metastasis",
                    "asFound": "Secondary",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10012",
                    "name": "Hyperparathyroidism",
                    "asFound": "Hyperparathyroidism",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10013",
                    "name": "Hyperparathyroidism, Secondary",
                    "asFound": "Secondary Hyperparathyroidism",
                    "relevance": "HIGH"
                },
                {
                    "id": "M26717",
                    "name": "Renal Insufficiency, Chronic",
                    "asFound": "Chronic Kidney Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M26718",
                    "name": "Renal Insufficiency",
                    "relevance": "LOW"
                },
                {
                    "id": "M17319",
                    "name": "Urologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27093",
                    "name": "Female Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14127",
                    "name": "Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8399",
                    "name": "Female Urogenital Diseases and Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M6147",
                    "name": "Chronic Disease",
                    "relevance": "LOW"
                },
                {
                    "id": "M22700",
                    "name": "Disease Attributes",
                    "relevance": "LOW"
                },
                {
                    "id": "M12330",
                    "name": "Neoplastic Processes",
                    "relevance": "LOW"
                },
                {
                    "id": "M13192",
                    "name": "Parathyroid Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M7862",
                    "name": "Endocrine System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T1303",
                    "name": "Chronic Graft Versus Host Disease",
                    "asFound": "Chronic",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M21860",
                    "name": "Pharmaceutical Solutions",
                    "relevance": "LOW"
                },
                {
                    "id": "M13194",
                    "name": "Parathyroid Hormone",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "PhSol",
                    "name": "Pharmaceutical Solutions"
                }
            ]
        }
    },
    "hasResults": false
}